![]() Scott, Jr., a founding partner and laboratory director of RMANJ, said “he team at McDermott was instrumental in completing this complex, cross-border transaction and we thank them for their commitment and diligence.”Ībout the Health Industry Advisory Group at McDermott Will & Emery In addition to Miami health care partner Bernard Grondin, the McDermott team representing RMANJ Management included McDermott partners Thomas Young and Carla Hine and associates Dana Dombey and Chelsea Rogers.ĭr. McDermott has become a go-to firm for healthcare work that does not originate in the US.” “As more and more of our US-based clients look to grow their businesses abroad, we are able to provide seamless cross-border representation with our international health team that includes health lawyers in the UK and in Germany, and with the strong relationships we have developed with local lawyers in key locations. “McDermott’s health care brand, already renowned in the US, has established its reputation in Europe and beyond, largely driven by our regulatory experience in the EU and across the world,” added Stephen Bernstein, global chair of McDermott’s Health Industry Advisory practice. “We are enormously pleased to be part of this groundbreaking transaction that will allow these two fertility leaders to collaborate and offer the best possible care to their patients worldwide,” added Dana Dombey, associate at McDermott. This business combination is representative of that trend and will accelerate advances in fertility treatments and services,” said McDermott partner Bernard Grondin who led the McDermott team. “The market for healthcare, especially driven by advancing technologies, is becoming more global. Last year alone, patients came to RMANJ from over 30 US states and 40 countries. In the last five years, RMANJ has grown nearly 70% in new patients. The combination of these platforms will create a unified global entity providing evidence-based fertility solutions that offer patients the greatest chances for success in the shortest time possible.įounded in 1999, RMANJ became one of the largest and most successful IVF programs in the US. IVI-RMA Global and its affiliated practices will have nearly 2,400 employees across 70 locations around the world, and will include a team of over 200 physicians, and over 300 scientists and researchers. One of IVI America’s core goals will be to expand the combined company’s footprint in the United States and Canada. IVI-RMA Global and its board of directors, which will be comprised of the founding partners of IVI and RMANJ, will oversee all international business units, including the newly-created IVI America. IVI-RMA Global will be the largest global fertility network providing assisted reproduction and related services. ($1 = 0.MIAMI (April 4, 2017) – International law firm McDermott Will & Emery served as legal adviser to the management division of Reproductive Medicine Associates of New Jersey (RMANJ Management), pioneers in the field of reproductive medicine, in connection with the execution of its business combination with The Valencian Infertility Institute (IVI) of Spain to create a new company called IVI-RMA Global, SL (IVI-RMA Global). With plentiful cash available, private equity firms have moved to invest in the sector, with KKR buying GeneraLife, one of Europe's largest fertility clinic groups, in November.ĮQT, meanwhile, sold its reproductive genetic testing services provider Igenomix to Swedish medical technology group Vitrolife in a deal worth 1.25 billion euros. The World Health Organization (WHO) estimates that 15% of reproductive-aged couples worldwide are affected by infertility, while Eurostat found that the average age of women giving birth to their first child in the EU was 29.4 years in 2019. The firm, which manages more than 75 clinics and 28 labs in nine countries, could be valued at between 16 and 17 times its core earnings of 120 million euros, one of the sources said. IVI's investors control 70% of the combined entity, while RMANJ has the balance. IVI-RMA was formed in 2017 when a group of doctors and investors from Spain's eastern region of Valencia merged IVI with U.S. Spain is one of Europe's largest markets for in-vitro fertilization (IVF) and is expected to be the main contributor to the region's overall IVF revenues, with a compound average growth rate (CAGR) of 7.21% due to an increase in fertility tourism and the high success rates of treatments, a study by Market Data Forecast said. Bain Capital and CVC were not immediately available to comment. Valencia-based IVI-RMA, KKR, Carlyle, Permira and PAI declined to comment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |